Previous Article | Next Article ![]()
Journal of Virology, March 2003, p. 3759-3767, Vol. 77, No. 6
0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.6.3759-3767.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Marjorie B. Kovler Viral Oncology Laboratories, University of Chicago, Chicago, Illinois,1 Section on Microbiology and Virology, Department of Experimental Pathology, University of Bologna, Bologna, Italy2
Received 29 October 2002/ Accepted 23 December 2002
|
|
|---|
1 helix (residue 77), in the immunoglobulin core and downstream regions (residue 151 and 187), and at the
3 helix (residues 243 and 246). Binding of soluble nectin1-Fc to cells expressing the mutant gDs was generally affected by the same mutations that affected fusion, with one notable exception (
277-310), which affected fusion without hampering nectin1 binding. This deletion likely identifies a region of gD involved in fusion activity at a post-nectin1-binding step. We conclude that whereas mutations that affected all functions (e.g., upstream connector region and residue 151) may be detrimental to overall gD structure, the mutations that affect specific activities identify domains of gD involved in the interactions with entry receptors and fusogenic glycoproteins and with cellular proteins required to block apoptosis. The evidence that glycosylation of gD is required for blocking apoptosis supports the conclusion that the interacting protein is the mannose-6 phosphate receptor. |
|
|---|
A central question investigated in this report is whether the antiapoptotic functions of gD overlap those of entry into cells, specifically those mediating the fusion of the envelope with the plasma membrane and binding to nectin1. In this report, we took advantage of a set of well-characterized gD insertion-deletion mutants generated by Chiang et al. (10) to map the domains necessary to block apoptosis and those critical for membrane fusion. The following observations are relevant to this report.
(i) We found that the distribution of HveA is mainly associated with cells of lymphoid origin (30). The interactions of gD with HveA have been studied at both the structural and genetic levels. Structural studies indicate that HveA binds at the amino terminus (8, 9, 21, 34). Genetic studies indicate that the interaction between gD and HveA is abolished by mutations at the amino terminus of gD and in the C-terminal portion of the ectodomain (residues 222 to 224) (15, 46).
(ii) Nectins form a family of intercellular adhesion molecules (17, 24, 37, 38, 41, 43). Structurally, they are members of the extended immunoglobulin superfamily. Nectin1 appears to be a major HSV receptor because of its ability to mediate entry as well as cell-to-cell spread of all HSV-1 and HSV-2 strains and its ubiquitous distribution in human tissues targeted by HSV (13, 14, 19). The nectin site that interacts with gD is in the N-terminal V-type domain (11, 12, 22, 25). Mutations at the amino terminus (residues 24 to 25) that abolish binding of gD with HveA do not affect the binding of gD to nectin1 (21). Studies in several laboratories have led to the conclusion that expression of gD on the cell surface sequesters nectin1 and HveA and blocks superinfection of the infected cell. This function, called restriction to infection or interference, stems from the ability of gD to interact in cis rather than in trans with the gD receptor, to sequester it, and to make it unavailable to superinfecting HSV (1, 5, 7, 18, 20).
(iii) Fusion of the envelope with the plasma membrane requires, in addition to gD, the glycoproteins B, H, and L. A cell-cell fusion assay based on coexpression of the four glycoproteins from expression vectors in HSV-susceptible cells was developed by Browne and coworkers (2). Inasmuch as the assay has two requirements in common with virion entry into cells (namely, coexpression of gD with gB, gH/gL, and the presence of one of the gD receptors in the target cell [36]), the cell-cell fusion mediated by the four glycoproteins is thought to mirror the basic fusion mechanism that takes place at virus entry into cells. A major advantage of the cell-cell fusion assay is that it can be readily quantified, whereas virus entry is usually quantified in an indirect manner, based on expression from the viral genome of a reporter gene (e.g., ß-galactosidase) placed under the control of an
promoter.
(iv) gD- mutants grown in complementing cells (gD-/+ stocks) contain gD in the envelope but lack the gD gene. gD- stocks produced in noncomplementing cells infected with gD-/+ virus (gD-/- stocks) lack both the gD gene and gD in the envelope. Both gD+/- and gD-/- stocks induce apoptosis that is characterized by translocation of annexin V and nucleosomal degradation of cellular DNA and blocked by gD delivered in trans (47).
The mechanism by which apoptosis is induced by gD-/- and gD-/+ stocks differs (47). gD-/- virus is taken up into endosome-like vesicles and degraded. Cells exposed to large numbers of gD-/- virus particles undergo apoptosis that is blocked by either intact gD or a heterodimer consisting of the ectodomain and transmembrane domain linked by disulfate bonds to the transmembrane domain and cytoplasmic tail of gD. Apoptosis induced by gD-/- virus is also blocked by chloroquine and by the cation-independent mannose-6 phosphate receptor (48). Earlier studies have shown that gD colocalizes with and binds mannose-6 phosphate receptor (3). More recent literature has shown that the mannose-6 phosphate receptor regulates the sorting of lysosomal enzymes and plays a role in apoptosis (50).
The picture that emerges from these studies is that gD interacts with and retains the mannose-6 phosphate receptor in the compartment containing the endocytosed virus particles, thereby preventing the release of lysosomal enzymes. Apoptosis induced by gD-/+ stocks is also blocked by gD and the mannose-6 phosphate receptor but not by chloroquine. Moreover, apoptosis induced by gD+/- stocks is blocked by the ectodomain of gD. Because gD-/+ stocks produce gD-/- particles in noncomplementing cells, one hypothesis that explains the accumulating data is that the secreted form of gD can interact with the mannose-6 phosphate receptor in a late endosomal compartment subverted for viral exocytosis to block the release of lysosomal enzymes (47-49).
Two sets of reagents have helped define the functional topology of gD. The first consists of a panel of monoclonal antibodies characterized for their ability to bind different sites of gD (33-35, 46). The second reagent consists of a panel of linker-scanning and deletion mutants of gD (10). Cells expressing the mutant forms of gD were used to complement a gD deletion virus (F-gD-ß) (23). The complemented virus was in turn assayed for the ability to infect Vero cells which express a simian isoform of nectin1 (10). Virus entry was quantified as percent complementation relative to that of virus grown in cells expressing wild-type gD. These studies led to the definition of four functional regions, I to IV, located at residues 27 to 43, 125 to 161, 225 to 246, and 277 to 310, respectively (10).
The crystal structure of a soluble truncated form of gD (gD285t) bound to HveA (see Fig. 8 in reference 9) showed that the gD ectodomain is composed of several structural regions. The N terminus (residues 1 to 32) of the molecule has no specific structure in the unbound state. It constitutes the HveA binding site and, upon binding, folds over itself, forming a hairpin. The core region (residues 56 to 184) adopts a V-like immunoglobulin structure made of two beta sheets composed of nine parallel and antiparallel ß strands. It is preceded by a connector sequence (residues 33 to 55) containing two ß strands. The immunoglobulin core region is followed by two additional ß strands. The downstream portion (residues 185 to 259) carries two
-helical structures and folds back towards the N-terminal hairpin. Its major
helix (
3) supports the hairpin. The structure of the most C-terminal portion of the ectodomain beyond residue 259 remains to be determined. The crystal structure of gD bound to nectin1 has not yet been solved.
The objectives of the studies presented in this report were twofold. The first was to map the domains of gD that are required to block apoptosis. Since the blocking of apoptosis appears to involve interaction with the mannose-6 phosphate receptor, this would be a first step in delineating the sites of interaction of gD with the mannose-6 phosphate receptor. These studies would also help determine whether the sites required for blocking apoptosis by gD-/- virus stocks differ from those required by the gD-/+ stocks. A second objective was to determine whether the domain required for blocking apoptosis overlapped the gD domains required to initiate cell-cell fusion and binding to nectin1. The studies were based on the panel of linker-scanning and deletion mutants described previously (10). We report that the domains of gD required to block apoptosis induced by gD-/- stocks could not be differentiated from those required for blocking the effects of gD-/+ stocks. However, the domains of gD required to block apoptosis were distinct from those involved in membrane fusion. In addition, the ability of gD to block apoptosis depends on its N-linked oligosaccharides, supporting the hypothesis that the antiapoptotic function of gD involves its interaction with the mannose-6 phosphate receptor.
|
|
|---|
Construction of recombinant baculoviruses expressing gD linker-insertion and linker-insertion-deletion mutants. The 19 plasmids including gD linker-insertion and linker-insertion-deletion mutants were described elsewhere (10). The locations of insertion and the inserted amino acids are shown in Table 1. The EcoRI-PstI fragments encoding the 19 mutant gDs were amplified by PCR with primers CGGAATTCATGGGGGGGGCTGCCGCCAG and AACTGCAGCTAGTAAAACAAGGGCTGGTGCG and inserted into the EcoRI and BglII sites of baculovirus transfer vector pAc-CMV (pMTS-1), a derivative of the pAcSG2 baculovirus transfer vector (PharMingen) in which the cytomegalovirus promoter sequence was inserted as a 756-bp fragment in the XhoI and EcoRI sites. All constructs were sequenced to ensure fidelity.
|
View this table: [in a new window] |
TABLE 1. gD linker-insertion and linker-insertion-deletion mutants
|
Construction of plasmids expressing HSV glycoproteins. The complete gB coding sequence was PCR amplified with primers 5'-GGCACGAGGCCTCCCCGTAGTCCCGCCATGC (forward) and 5'-GATGCACATGAGATCTAACACCCGTGG (reverse) and cloned as a StuI-BglII fragment in the corresponding sites of pMTS-1. The complete gH coding sequence was PCR amplified with primers 5'-CCCCC ATGGG CGGCC GCTTA TGGTT CGTG (forward) and 5'-ACCAC AGACA CGGTT AACGT TTATT CG (reverse) and cloned as a NotI-HpaI fragment in the NotI and SmaI sites of pMTS-1. The complete gL sequence was PCR amplified with primers 5'-GACTG TAGGC CTCTG TGGGT GCCGA C (forward) and 5'-GTTCGCCCCCGGTACCCGGACGGGTTTC (reverse) and cloned as a StuI-Asp718 fragment in the MTS-1 vector. The pEA99 plasmid carrying the gD coding sequence in pcDNA3.1(-) was described previously (28) and obtained by amplification of the gD coding sequence of HSV-1(F) gD (25 bp upstream of the start codon and 34 bp downstream of the stop codon) with primers 5'-TATCCTTAAGGGATCCTTTGTGTGGTGCG (forward) and 5'GGTCTGCGGGGTAAGCTTGGGACCTTA (reverse).
Baculoviruses expressing HSV-1 glycoproteins. Recombinant baculoviruses expressing HSV-1 gB, gH, and gL were obtained by cotransfecting the corresponding baculovirus transfer vectors gB-MTS, gL-MTS, and gH-MTS with BaculoGold DNA (Pharmingen) in Sf9 insect cells as specified by the Pharmingen protocol. The baculovirus expressing gD was described previously (47).
Double infections. Subconfluent cultures of SK-N-SH cells in 25-cm2 flasks were first exposed at 37°C for 2 h to 10 PFU of recombinant baculovirus per cell and then to either 100 PFU equivalent of gD-/- or 10 PFU of gD-/+ mutant HSV-1 viruses per cell. The cultures were then maintained for an additional 24 h at 37°C in medium containing 2.5 mM sodium butyrate.
DNA fragmentation assay. The assays for fragmentation of cellular DNA were described elsewhere (47).
Fusion assay. Subconfluent cultures of BHK or 143TK- cells grown on glass coverslips in 24-well plates were transfected with a DNA mixture containing 80 ng each of the HSV1-glycoprotein-expressing vectors and the pcDNA3.1(-) Myc-His/Lac vector (Invitrogen) for constitutive expression of ß-galactosidase. The total amount of DNA transfected per well was kept at 400 ng by addition of empty MTS vector DNA. Transfections were performed with Lipofectamine (Life Technologies) according to the manufacturer's instructions. After incubation at 37°C for 20 h, the transfection mixture was replaced with fresh medium; cells were incubated for an additional 30 h and then fixed with 0.2% glutaraldehyde and 0.2% paraformaldehyde in phosphate-buffered saline.
Syncytia were detected by light microscopy observation of ß-galactosidase-expressing cells after staining with 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside (X-Gal) with a Leitz microscope equipped with a Kodak DC120 photocamera and Kodak Digital Science 1D LE 3.0 software. The percentage of cells expressing ß-galactosidase was quantified by means of the Photoshop Histogram program as detailed previously (13). In each case, the value obtained for a replicate sample containing only gD or the Myc-His/Lac vector was subtracted. All mutants were assayed in three independent experiments with two different plasmid DNA preparations.
Binding of soluble nectin1-Fc to mutant gD-expressing cells. Binding was measured by cell enzyme-linked immunosorbent assay. Briefly, BHK cells were transfected in 24-well trays with 300 ng of DNA from each gD mutant. At 24 or 48 h after transfection, cells were blocked for 30 min at room temperature with 10% fetal bovine serum diluted in phosphate-buffered saline, incubated for 60 min at 4°C with nectin1-Fc (0.6 ng/µl), and fixed with 4% paraformaldehyde. Fixed cells were sequentially incubated with biotinylated anti-human immunoglobulin G (Sigma), extravidin-horseradish peroxidase (Sigma), and a substrate solution containing o-phenylenediamine (Sigma). The reaction was stopped with sulfuric acid, and the optical density was read at 490 nm in a Bio-Rad microplate reader. Each sample was run in duplicate.
|
|
|---|
The region responsible for blocking apoptosis induced by gD-/+ maps to three discontinuous sites.
SK-N-SH cells infected with recombinant baculoviruses were infected with 100 PFU equivalents of gD-/- virus per cell, harvested 24 h later, and examined for the presence of fragmented DNA. The results reported in Fig. 1A and summarized in Table 2 show that the gD mutations that enabled apoptosis mapped at three sites, (i)
12-77,
34, and
43, (ii)
125,
126, and
151, and (iii)
277. These mutations fall into functional regions I, II, and IV, which correspond to structures outside the immunoglobulin core, within the core, and downstream of the core, respectively. Of the two deletion mutants (
12-77 and
277-310), only the former failed to block apoptosis.
![]() View larger version (86K): [in a new window] |
FIG. 1. Agarose gel containing electrophoretically separated DNA from cells infected first with recombinant baculoviruses expressing linker-insertion and linker-insertion-deletion mutant gDs and then with the gD-/- and gD-/+ virus stocks. Replicate cultures of subconfluent SK-N-SH cells in 25-cm2 flasks were infected with 10 PFU of the indicated recombinant baculovirus per cell for 2 h, and then the cells were exposed to 100 PFU equivalents of gD-/- (A) or 10 PFU of gD-/+ (B) virus stock per cell. The cells were harvested at 24 h after gD-/+ infection and processed as described in Materials and Methods.
|
|
View this table: [in a new window] |
TABLE 2. Effect of mutations on antiapototic and fusion activity of gD
|
![]() View larger version (61K): [in a new window] |
FIG. 5. Schematic backview of the crystal structure of gD (from reference 9) in which the mutations that block apoptosis and those that affect cell-cell fusion have been highlighted in fuchsia and in blue, respectively.
|
![]() View larger version (96K): [in a new window] |
FIG. 2. Agarose gel containing electrophoretically separated DNA from cells infected with recombinant baculoviruses expressing mutant gD(QAA) and then with the gD-/- and gD-/+ virus stocks. Subconfluent SK-N-SH cells in 25-cm2 flasks were infected with the indicated amount of recombinant baculovirus per cell for 2 h. Then the cells were exposed either to 100 PFU equivalents of gD-/- virus stock per cell (A) or to 10 PFU of gD-/+ virus stock per cell (B). The cells were harvested at 24 h after gD-/+ infection and processed as described in Materials and Methods.
|
Cell-cell fusion mediated by gD mutants. The cell-cell fusion assay was performed in three different cell lines, BHK, human 143TK-, and SK-N-SH. BHK cells express a hamster homolog of human nectin1, 143 cells express human nectin1, and SK-N-SH express both human nectin1 and HveA (14, 29, 47). We observed that different cells lines exhibit strong variations in the ability to undergo fusion when cotransfected with wild-type gD and gB, gH, and gL. Thus, BHK cells give rise to massive polykaryocytes, whereas those formed in 143TK- cells contain few nuclei. Because of their small size, the polykaryocytes in 143TK- cells were scored as either absent (-) or present (+). The results with 143TK- cells were therefore scored following microscopic observations by three independent investigators.
SK-N-SH cells proved resistant to glycoprotein expression following transfections. We tried to overcome this obstacle by expressing the four glycoproteins through baculovirus infection and treatment with 2 mM sodium butyrate. In this way, the four glycoproteins were expressed, but we could only observe very tiny syncytia. A comparative study of the gD mutants could not be carried out in these cells.
Representative results with BHK and 143TK- cells are shown in Fig. 3A to D for 143TK- cells and Fig. 3E to H for BHK cells. Quantitative results of a typical experiment with BHK cells are shown in Fig. 4A, summarized in Table 2, and schematically represented against the crystal structure of gD in Fig. 5. Notwithstanding the differences in the sizes of polykaryocytes formed in the two cell lines, there was an overall correspondence between the fusion ability of the gD mutants in BHK and 143 cells. Some minor discrepancies may reflect differences in the inherent composition of the plasma membranes that are also reflected in the size of the polykaryocytes and/or the ease of detection of polykaryocytes in BHK cells. The fusion activity was arbitrarily considered positive when it accounted for 25% of that attained with wild-type gD (dashed line in Fig. 4A). The samples whose syncytia constituted between 15 and 25% of the areas of syncytia obtained with wild-type gD were marked as ±. Overall, mutations at four sites disrupted the ability to form polykaryocytes dependent on the interaction of gD with human or hamster nectin1. They mapped at residues 34 and 43, located upstream of the core region; residues 77 and 151, within the immunoglobulin core; and residues 187, 243, and 246 downstream of it (Fig. 5). The former mutations (34 and 43) coincide with those that cause inability to block apoptosis, whereas the latter (77b, 187, 243, and 246d) do not (with the exception of mutant 151). Both deletion mutants (
12-77 and
277-310) were ineffective in cell-cell fusion.
![]() View larger version (114K): [in a new window] |
FIG. 3. Representative examples of polykaryocytes in 143TK- cells (A to D) or BHK cells (E to H) induced in BHK cells. 143TK- cells were cotransfected with plasmids encoding gB, gH/gL, and a mutant gD or wild-type gD, together with a plasmid encoding lacZ. Transfected cells were stained with X-Gal. (A) Wild-type gD. (B) 77a. (C) 77b. (D) gD alone. BHK cells were cotransfected with plasmids encoding gB, gH/gL, and a mutant gD or wild-type gD, together with a plasmid encoding lacZ. Transfected cells were stained with X-Gal at 40 h after transfection. (E) Wild-type gD. (F) 77a. (G) 77b. (H) Background resulting from transfection of wild-type gD in the absence of other glycoproteins.
|
![]() View larger version (40K): [in a new window] |
FIG. 4. Quantitation of fusion activity induced in BHK cells by gD mutants (A) and quantitation of binding of mutant gDs to nectin1-Fc (B). (A) BHK cells were cotransfected with plasmids encoding gB, gH/gL, and a mutant gD or wild-type gD (gD wt), together with a plasmid encoding lacZ. Transfected cells were stained with X-Gal at 40 h after transfection. Micrographs were taken with a Leitz microscope equipped with a photocamera and Kodak Digital Science 1D LE 3.0 software. Percentage of cells expressing ß-galactosidase was quantified by means of the Photoshop Histogram program, as previously detailed (13). In each case, the value obtained for a replicate sample containing only gD or the Myc-His/Lac vector was subtracted. Thin bars denote standard deviation. Samples that gave rise to syncytia whose areas were between 15 and 25% of those attained with wild-type gD were considered ±. Samples whose syncytia had an area >25% of the area obtained with wild-type gD (dashed line) were considered positive and are indicated as such in Table 2. (B) Quantitation of binding of mutant gDs to nectin1-Fc. Duplicate samples of BHK cells were transfected with 300 ng of DNA from each gD mutant. At 24 h posttransfection, cells were reacted with nectin1-Fc, followed by biotinylated anti-human immunoglobulin G and extravidin-horseradish peroxidase. Samples whose binding activity was below 25% of that attained with wild-type gD are within the limits of detection and are marked as negative in Table 2. ±, binding around the 25% cutoff value (dotted line). OD, optical density.
|
gD virus (42).
Binding of mutant gDs to soluble nectin1-Fc.
The experiment testing binding of mutant gDs to soluble nectin1-Fc was designed to identify the mutations that affect binding of soluble nectin1-Fc to mutant gDs and to verify whether some mutations can affect cell-cell fusion without decreasing nectin1 binding. Mutant gDs were expressed in BHK cells by transfection. Transfected cells were then incubated with soluble nectin1-Fc, generated as described before (12). The results are shown in Fig. 4B and summarized in Table 2. As none of the mutants was previously reported to be defective in cell surface expression, lack of binding to nectin1 should reflect alteration in the nectin1 binding site. Overall, the mutations that reduced binding coincided with those that reduced fusion, with two sets of exceptions. The 77a, 125, and 126 mutants strongly reduced binding without significantly affecting fusion. In this case, binding may be below the limit of detection but sufficient to mediate fusion. A remarkable difference was that observed with the
277-310 mutant. This deletion abolished fusion but left a significant level of binding.
|
|
|---|
As reported elsewhere, gD-/- and gD-/+ viruses differ in the minimal structure of gD that is delivered in trans and required to block apoptosis. Whereas gD-/- stocks require a protein comprising all of the sequences of gD, albeit not in a single polypeptide, only the ectodomain of gD is required to block the apoptosis induced by gD-/+ mutant stocks (46-49). Notwithstanding these differences, the mutations that resulted in failure to block apoptosis by gD-/- stocks also failed to block apoptosis by gD-/+ stocks. The observations that gD-/- and gD-/+ stocks require identical domains to block apoptosis support the conclusion that gD blocks apoptosis by interacting with the same cellular proteins but, as described elsewhere, in two different compartments of the infected cell (47-49).
It is noteworthy that these mutations were located at three positions, one outside the immunoglobulin core region and located in the connector region between the hairpin and the immunoglobulin core (key residues 34 and 43), the second within the immunoglobulin core region (residues 125, 126, and 151), and the third in the carboxyl terminus of the ectodomain (residue 277). Of these, the insertions at residues 34, 43, and 151 affected all assayed functions of gD and their effects most likely reflect a detrimental effect on the structure of gD and not a site required for a specific interaction of gD with a cellular protein involved in apoptosis. Thus, residue 151 falls into ß-strand E of the immunoglobulin core (Fig. 5). This insertion is likely to disrupt the ß-strand itself, to perturb its bonds with the adjacent ß-strands, and thus to affect the structure of the immunoglobulin core. The antiapoptotic domain therefore appears to involve residues or regions around residues 125 to 126 and 277.
Several lines of evidence reported elsewhere indicate that gD interacts with the mannose-6 phosphate receptor to block apoptosis (4, 48, 50). One requirement for this interaction is that gD must be at least glycosylated. In this report we show that a gD mutant in which all three N-glycosylation sites were mutated failed to block apoptosis while maintaining the competence to mediate cell fusion and nectin1 binding, two properties consistent with its ability to complement the infectivity of
gD virus (42). This observation is consistent with the idea that gD and the mannose-6 phosphate receptor colocalize and interact in the endosomal compartment and that this interaction is necessary to block apoptosis resulting from release of lysosomal enzymes (3, 4, 48).
The results of the cell-cell fusion in hamster (BHK) and human (143 and SK-N-SH) cells showed remarkable differences in the extent to which different cell lines were prone to form polykaryocytes, including the number of cells recruited into average-sized polykaryocytes. This in turn may affect the readout of the results, as mutant gDs with reduced ability to form polykaryocytes may appear to be negative in a cell line with an innate aversion to polykaryocytosis. This conclusion is in accord with observations published earlier to the effect that with the exception of a few virus strains, (e.g., the MP strain), the formation of polykaryocytes by syn mutant strains is cell type dependent (40). Irrespective of the innate differences, the effects of gD mutations on cell-cell fusion in BHK and 143TK- cells did not differ substantially (Table 2).
All mutant gDs were previously shown not to be defective in cell surface expression (10). Taking into account that the mutations likely to reflect specific interactions are those that did not simultaneously affect all the measured functions of gD, the mutations affecting fusion were located in the additional
1 helix present within the immunoglobulin core (residue 77), in the core downstream region that folds back towards the N terminus and carries the
3 helix (residues 187, 243, and 246), and in the
277-310 mutant. In particular, residues 77 and 187 appear to be located in unstructured, highly exposed regions of gD (Fig. 5) that may represent convenient sites of contact. In turn, the sites involved in fusion may reflect two sets of interactions, those between the receptor (nectin1) and gD and those between gD alone (or the receptor-gD complex) and the set of proteins involved in the cell-cell fusion.
We observed an overall agreement between the mutations that disrupted fusion activity and those that reduced binding to nectin1, with two exceptions. In those cases where binding was low but fusion was unaffected (mutations 77a, 125, 126, and 277), it is likely that binding was low or below the limits of detection but sufficient to mediate fusion. This is similar to what was observed with murine nectin1, a receptor competent to mediate HSV entry into cells, although its binding to gD is, at best, very weak (26-28). The dissociation between fusion and binding was observed with the
277-310 mutant, which was capable of binding but incapable of fusion. One hypothesis that could explain this result is that mutagenesis of this site enables attachment but affects a site involved in a postattachment function required for cell-cell fusion. This hypothesis is consistent with several lines of evidence indicating that the C-terminal portion of the ectodomain carries epitopes recognized by neutralizing monoclonal antibodies and is important for the ability of soluble gD to compete with virus entry (10, 31, 32, 46). More specifically, earlier studies have shown that the mutant lacking residues 277 to 310 has a very high affinity for both HveA and nectin1.
It can be seen from Table 2 that the mutations that hampered fusion activity and/or nectin1 binding generally reduced virus entry. Two exceptions were
187 and
246a, which in some respects was no surprise. They may reflect the fact that fusion and infectivity were assayed in different cellular systems, implying that the receptor interacting with gD as well as the fusion factors provided by the cells differed between the two systems. Furthermore, the cell-cell fusion assay mirrors virus entry but is not necessarily an identical process and is not subject to the control exerted by additional viral proteins. Thus, while all fresh isolates by definition enter cells, few if any form polykaryocytes in cells in culture. Failure to fuse cells may reflect different structural requirements, since syn mutations map to several different glycoproteins. Altogether, these results highlight differences in the structural requirements for fusion activity and for virus entry that may help in dissecting the two phenomena.
In essence, our data highlight three functional domains in gD located at nonoverlapping regions, one antiapoptotic domain, one nectin1-binding domain involved in gD fusion, and one site involved in fusion independent of nectin1-binding activity, likely at a post-nectin1-binding step. The additional independent domain characterized in previous studies is that involved in HveA interaction, located at the N terminus of the molecule (15, 16, 46). Interestingly, most of the mutations that affect functional domains lie predominantly outside the immunoglobulin core structure. The model that emerges from our studies is that the immunoglobulin core provides a scaffold for the molecule and binding sites for the proteins with which gD interacts lie predominantly in additional structural domains of gD.
The studies done at the University of Chicago were aided by grants from the National Cancer Institute (CA78766, CA71933, CA83939, CA87661, and CA88860), U.S. Public Health Service. The studies at the University of Bologna were supported by grants from Cofin-MUIR, FIRB, 2001 and 2002, University of Bologna.
|
|
|---|
serves as a species nonspecific mediator for entry of human and animal
herpesviruses in a pathway independent of a detectable binding to gD. Proc. Natl. Acad. Sci. USA 97:4867-4872.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»